CoChat

Hepcidin Therapeutics

Open access
Katsarou, Angeliki, Pantopoulos, Kostas · 2018 · Pharmaceuticals
Cited by 112

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

Hepcidin is a key hormonal regulator of systemic iron homeostasis and its expression is induced by iron or inflammatory stimuli. Genetic defects in iron signaling to hepcidin lead to “hepcidinopathies” ranging from hereditary hemochromatosis to iron-refractory iron deficiency anemia, which are disorders caused by hepcidin deficiency or excess, respectively. Moreover, dysregulation of hepcidin is a pathogenic cofactor in iron-loading anemias with ineffective erythropoiesis and in anemia of inflammation. Experiments with preclinical animal models provided evidence that restoration of appropriate hepcidin levels can be used for the treatment of these conditions. This fueled the rapidly growing field of hepcidin therapeutics. Several hepcidin agonists and antagonists, as well as inducers and inhibitors of hepcidin expression have been identified to date. Some of them were further developed and are currently being evaluated in clinical trials. This review summarizes the state of the art.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph11040127

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Research works printed but not linked: 103

  1. Papanikolaou, 2017, Systemic iron homeostasis and erythropoiesis, IUBMB Life, 69, 399, 10.1002/iub.1629 · DOI
  2. Pandur, 2018, The C19S Substitution Enhances the Stability of Hepcidin While Conserving Its Biological Activity, Protein J., 37, 113, 10.1007/s10930-018-9759-9 · DOI
  3. Wahedi, 2017, Matriptase-2 suppresses hepcidin expression by cleaving multiple components of the hepcidin induction pathway, J. Biol. Chem., 292, 18354, 10.1074/jbc.M117.801795 · DOI
  4. Mayeur, 2014, The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6, Blood, 123, 2261, 10.1182/blood-2013-02-480095 · DOI · Paper page
  5. Gineste, 2017, Hepcidin upregulation by inflammation is independent of Smad1/5/8 signaling by activin B, Blood, 129, 533, 10.1182/blood-2016-10-748541 · DOI
  6. Latour, 2017, Deletion of BMP6 worsens the phenotype of HJV-deficient mice and attenuates hepcidin levels reached after LPS challenge, Blood, 130, 2339, 10.1182/blood-2017-07-795658 · DOI · Paper page
  7. Fillebeen, 2018, Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling, Blood, 132, 1829, 10.1182/blood-2018-03-841197 · DOI
  8. Pantopoulos, 2018, Inherited Disorders of Iron Overload, Front. Nutr., 5, 103, 10.3389/fnut.2018.00103 · DOI
  9. Gupta, 2018, Ineffective Erythropoiesis: Anemia and Iron Overload, Hematol. Oncol. Clin. N. Am., 32, 213, 10.1016/j.hoc.2017.11.009 · DOI · Paper page
  10. Kowdley, 2016, Iron Overload in Patients with Chronic Liver Disease, Gastroenterol. Hepatol. (N. Y.), 12, 695
  11. Vela, 2018, Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker, Mol. Med., 24, 5, 10.1186/s10020-018-0008-7 · DOI
  12. Han, 2016, Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt, Nat. Commun., 7, 13817, 10.1038/ncomms13817 · DOI
  13. Folgueras, 2018, Matriptase-2 deficiency protects from obesity by modulating iron homeostasis, Nat. Commun., 9, 1350, 10.1038/s41467-018-03853-1 · DOI · Paper page
  14. Heeney, 2014, Iron-Refractory Iron Deficiency Anemia (IRIDA), Hematol. Oncol. Clin. N. Am., 28, 637, 10.1016/j.hoc.2014.04.009 · DOI
  15. Fraenkel, 2017, Anemia of Inflammation: A Review, Med. Clin. N. Am., 101, 285, 10.1016/j.mcna.2016.09.005 · DOI · Paper page
  16. Ueda, 2017, Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond, Curr. Med. Chem., 24, 1417, 10.2174/0929867324666170316120538 · doi:10.2174/0929867324666170316120538
  17. Nairz, 2016, Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation, Wien. Med. Wochenschr., 166, 411, 10.1007/s10354-016-0505-7 · DOI · Paper page
  18. You, 2017, Astrocyte hepcidin is a key factor in LPS-induced neuronal apoptosis, Cell Death Dis., 8, e2676, 10.1038/cddis.2017.93 · DOI · Paper page
  19. Pinnix, 2010, Ferroportin and iron regulation in breast cancer progression and prognosis, Sci. Transl. Med., 2, 43ra56, 10.1126/scitranslmed.3001127 · DOI · Paper page
  20. Zhou, 2018, E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin, Cell Death Dis., 9, 987, 10.1038/s41419-018-1001-3 · DOI
  21. Casu, 2018, Hepcidin agonists as therapeutic tools, Blood, 131, 1790, 10.1182/blood-2017-11-737411 · DOI · Paper page
  22. Sivakumar, 2016, Management of human factors engineering-associated hemochromatosis: A 2015 update, World J. Hepatol., 8, 395, 10.4254/wjh.v8.i8.395 · DOI
  23. Niederau, 1985, Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis, N. Engl. J. Med., 313, 1256, 10.1056/NEJM198511143132004 · DOI · Paper page
  24. Musallam, 2013, Cross-talk between available guidelines for the management of patients with beta-thalassemia major, Acta Haematol., 130, 64, 10.1159/000345734 · DOI
  25. Besarab, 2010, Iron supplementation to treat anemia in patients with chronic kidney disease, Nat. Rev. Nephrol., 6, 699, 10.1038/nrneph.2010.139 · DOI
  26. Biggar, 2017, Treatment of renal anemia: Erythropoiesis stimulating agents and beyond, Kidney Res. Clin. Pract., 36, 209, 10.23876/j.krcp.2017.36.3.209 · DOI
  27. Tzounakas, 2017, Red blood cell transfusion in surgical cancer patients: Targets, risks, mechanistic understanding and further therapeutic opportunities, Transfus. Apheresis Sci., 56, 291, 10.1016/j.transci.2017.05.015 · DOI
  28. Guo, 2013, Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice, J. Clin. Investig., 123, 1531, 10.1172/JCI66969 · DOI · Paper page
  29. Casu, 2016, Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia, Haematologica, 101, e8, 10.3324/haematol.2015.133348 · DOI · Paper page
  30. Aghajan, 2016, Developing a Galnac-Conjugated TMPRSS6 Antisense Therapy for the Treatment of β-Thalassemia, Blood, 128, 1013, 10.1182/blood.V128.22.1013.1013 · doi:10.1182/blood.v128.22.1013.1013
  31. Schmidt, 2018, RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of beta-thalassemia intermedia, Am. J. Hematol., 93, 745, 10.1002/ajh.25079 · DOI
  32. Patchen, 2016, Dietary supplementation with ipriflavone decreases hepatic iron stores in wild type mice, Blood Cells Mol. Dis., 60, 36, 10.1016/j.bcmd.2016.05.004 · DOI
  33. Call, 2017, Imatinib and spironolactone suppress hepcidin expression, Haematologica, 102, 1173, 10.3324/haematol.2016.162917 · DOI
  34. Zhang, 2016, Icariin regulates systemic iron metabolism by increasing hepatic hepcidin expression through Stat3 and Smad1/5/8 signaling, Int. J. Mol. Med., 37, 1379, 10.3892/ijmm.2016.2545 · DOI
  35. Bayele, 2015, Phytoestrogens modulate hepcidin expression by Nrf2: Implications for dietary control of iron absorption, Free Radic. Biol. Med., 89, 1192, 10.1016/j.freeradbiomed.2015.11.001 · DOI
  36. Zhang, 2018, Adenine alleviates iron overload by cAMP/PKA mediated hepatic hepcidin in mice, J. Cell. Physiol., 233, 7268, 10.1002/jcp.26559 · DOI
  37. Mendez, 2010, Hepcidin treatment in Hfe−/− mice diminishes plasma iron without affecting erythropoiesis, Eur. J. Clin. Investig., 40, 511, 10.1111/j.1365-2362.2010.02291.x · DOI · Paper page
  38. Fung, 2015, Thiol-derivatized minihepcidins retain biological activity, Bioorg. Med. Chem. Lett., 25, 763, 10.1016/j.bmcl.2014.12.094 · DOI
  39. Lunova, 2017, Hepcidin knockout mice spontaneously develop chronic pancreatitis owing to cytoplasmic iron overload in acinar cells, J. Pathol., 241, 104, 10.1002/path.4822 · DOI
  40. Chua, 2015, Small cyclic agonists of iron regulatory hormone hepcidin, Bioorg. Med. Chem. Lett., 25, 4961, 10.1016/j.bmcl.2015.03.012 · DOI
  41. Lal, A., Piga, A., Viprakasit, V., Maynard, J., Kattamis, A., Yaeger, D., Byrnes, B., Chawla, L., and Tidmarsh, G. (2018, January 14–17). A phase 1, open-label study to determine the safety, tolerability, and pharmacokinetics of escalating doses of LJPC-401 (synthetic human hepcidin) in patients with iron overload. Proceedings of the 23rd European Hematology Association Congress, Stockholm, Sweden. Abstract #S894.
  42. Bourne, G., Zhao, L., Bhandari, A., Frederick, B., McMahon, J., Tran, V., Annamalai, T., Mattheakis, L., Patel, D., and Smythe, M. (2018, January 14–17). Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Chronic Anemia in Hemoglobinopathy Disease. Proceedings of the 23rd European Hematology Association Congress, Stockholm, Sweden. Abstract #S843.
  43. Nicholls, A., Lickliter, J., Tozzi, L., Liu, D., and Shames, R. (2018, January 14–17). Hepcidin mimetic PTG-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy subjects. Proceedings of the 23rd European Hematology Association Congress, Stockholm, Sweden. Abstract #S895.
  44. Abreu, 2018, Heparin inhibits intracellular Mycobacterium tuberculosis bacterial replication by reducing iron levels in human macrophages, Sci. Rep., 8, 7296, 10.1038/s41598-018-25480-y · DOI
  45. Poli, 2014, Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo, Blood, 123, 1564, 10.1182/blood-2013-07-515221 · DOI · Paper page
  46. Poli, 2014, Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo, Biochem. Pharmacol., 92, 467, 10.1016/j.bcp.2014.09.007 · DOI
  47. Seldin, 2014, Metabolic function of the CTRP family of hormones, Rev. Endocr. Metab. Disord., 15, 111, 10.1007/s11154-013-9255-7 · DOI · Paper page
  48. Babitt, 2007, Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance, J. Clin. Investig., 117, 1933, 10.1172/JCI31342 · DOI · Paper page
  49. Kovac, 2016, Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels, Haematologica, 101, e173, 10.3324/haematol.2015.140772 · DOI · Paper page
  50. Yu, 2008, Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism, Nat. Chem. Biol., 4, 33, 10.1038/nchembio.2007.54 · DOI · Paper page
  51. Kanamori, 2016, Regulation of hepcidin expression by inflammation-induced activin B, Sci. Rep., 6, 38702, 10.1038/srep38702 · DOI
  52. Vogt, 2011, The specificities of small molecule inhibitors of the TGFss and BMP pathways, Cell. Signal., 23, 1831, 10.1016/j.cellsig.2011.06.019 · DOI · Paper page
  53. Mohedas, 2013, Development of an ALK2-biased BMP type I receptor kinase inhibitor, ACS Chem. Biol., 8, 1291, 10.1021/cb300655w · DOI · Paper page
  54. Mu, 2016, The dietary flavonoid myricetin regulates iron homeostasis by suppressing hepcidin expression, J. Nutr. Biochem., 30, 53, 10.1016/j.jnutbio.2015.10.015 · DOI
  55. Fukuda, 2017, Synthesis and SAR studies of 3,6-disubstituted indazole derivatives as potent hepcidin production inhibitors, Bioorg. Med. Chem. Lett., 27, 2148, 10.1016/j.bmcl.2017.03.056 · DOI
  56. Fukuda, 2017, Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives, Bioorg. Med. Chem. Lett., 27, 5252, 10.1016/j.bmcl.2017.10.031 · DOI
  57. Fukuda, 2017, Discovery of DS79182026: A potent orally active hepcidin production inhibitor, Bioorg. Med. Chem. Lett., 27, 3716, 10.1016/j.bmcl.2017.07.004 · DOI
  58. Sasaki, 2018, Target identification of hepcidin production inhibitors by a combination of chemical proteomics and radioactive compound binding assay, Biochem. Biophys. Res. Commun., 503, 2878, 10.1016/j.bbrc.2018.08.061 · DOI
  59. Peterson, 2016, The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease (Abstract), Blood, 128, 263, 10.1182/blood.V128.22.263.263 · DOI
  60. Pardanani, 2013, Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis, Leukemia, 27, 1322, 10.1038/leu.2013.71 · DOI · Paper page
  61. Kuhrt, 2015, Emerging EPO and EPO receptor regulators and signal transducers, Blood, 125, 3536, 10.1182/blood-2014-11-575357 · DOI · Paper page
  62. Asshoff, 2017, Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents, Blood, 129, 1823, 10.1182/blood-2016-09-740092 · DOI · Paper page
  63. Jones, 2010, Tocilizumab: A review of its safety and efficacy in rheumatoid arthritis, Clin. Med. Insights Arthritis Musculoskelet. Disord., 3, 81, 10.4137/CMAMD.S4864 · DOI
  64. Song, 2013, Comparative evaluation of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients, Arthritis Res. Ther., 15, R141, 10.1186/ar4323 · DOI · Paper page
  65. Suzuki, 2017, Hepcidin-25 gives an indication of the therapeutic effectiveness of tocilizumab in rheumatoid arthritis—Relationship between disease activity of rheumatoid arthritis and anemia, Rev. Bras. Reumatol. Engl. Ed., 57, 637, 10.1016/j.rbr.2016.07.004 · DOI
  66. Noguchi-Sasaki, M., Sasaki, Y., Shimonaka, Y., Mori, K., and Fujimoto-Ouchi, K. (2016). Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells. BMC Cancer, 16. · DOI
  67. Laine, 2017, Curcuma decreases serum hepcidin levels in healthy volunteers: A placebo-controlled, randomized, double-blind, cross-over study, Fundam. Clin. Pharmacol., 31, 567, 10.1111/fcp.12288 · DOI
  68. Li, W.Y., Li, F.M., Zhou, Y.F., Wen, Z.M., Ma, J., Ya, K., and Qian, Z.M. (2016). Aspirin down Regulates Hepcidin by Inhibiting NF-kappaB and IL6/JAK2/STAT3 Pathways in BV-2 Microglial Cells Treated with Lipopolysaccharide. Int. J. Mol. Sci., 17. · DOI
  69. Huang, 2018, Aspirin increases ferroportin 1 expression by inhibiting hepcidin via the JAK/STAT3 pathway in interleukin 6-treated PC-12 cells, Neurosci. Lett., 662, 1, 10.1016/j.neulet.2017.10.001 · DOI
  70. Marcon, 2013, Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis, J. Immunol., 191, 4288, 10.4049/jimmunol.1202743 · DOI · Paper page
  71. Wang, 2016, Maresin 1 ameliorates iron-deficient anemia in IL-10(−/−) mice with spontaneous colitis by the inhibition of hepcidin expression though the IL-6/STAT3 pathway, Am. J. Transl. Res., 8, 2758
  72. Liu, 2012, Polysaccharide isolated from Angelica sinensis inhibits hepcidin expression in rats with iron deficiency anemia, J. Med. Food, 15, 923, 10.1089/jmf.2012.2231 · DOI
  73. Wang, 2017, Acidic Polysaccharide from Angelica sinensis Reverses Anemia of Chronic Disease Involving the Suppression of Inflammatory Hepcidin and NF-kappaB Activation, Oxid. Med. Cell. Longev., 2017, 7601592, 10.1155/2017/7601592 · DOI
  74. Wang, 2018, Correction of Anemia in Chronic Kidney Disease with Angelica sinensis Polysaccharide via Restoring EPO Production and Improving Iron Availability, Front. Pharmacol., 9, 803, 10.3389/fphar.2018.00803 · DOI
  75. Olas, 2015, Hydrogen sulfide in signaling pathways, Clin. Chim. Acta, 439, 212, 10.1016/j.cca.2014.10.037 · DOI · Paper page
  76. Xin, 2016, Hydrogen Sulfide Attenuates Inflammatory Hepcidin by Reducing IL-6 Secretion and Promoting SIRT1-Mediated STAT3 Deacetylation, Antioxid. Redox Signal., 24, 70, 10.1089/ars.2015.6315 · DOI
  77. Wang, M., Tang, W., Xin, H., and Zhu, Y.Z. (2016). S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway. PLoS ONE, 11. · DOI
  78. Wang, 2017, AMPK Serves as a Therapeutic Target Against Anemia of Inflammation, Antioxid. Redox Signal., 27, 251, 10.1089/ars.2016.6846 · DOI
  79. Angmo, 2017, Identification of Guanosine 5′-diphosphate as Potential Iron Mobilizer: Preventing the Hepcidin-Ferroportin Interaction and Modulating the Interleukin-6/Stat-3 Pathway, Sci. Rep., 7, 40097, 10.1038/srep40097 · DOI
  80. Guo, 2013, Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells, Aging Cell, 12, 280, 10.1111/acel.12052 · DOI · Paper page
  81. Ohlander, 2018, Erythrocytosis Following Testosterone Therapy, Sex. Med. Rev., 6, 77, 10.1016/j.sxmr.2017.04.001 · DOI · Paper page
  82. Guo, 2016, Effects of Testosterone on Erythropoiesis in a Female Mouse Model of Anemia of Inflammation, Endocrinology, 157, 2937, 10.1210/en.2016-1150 · DOI
  83. Bachman, 2014, Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: Evidence for a new erythropoietin/hemoglobin set point, J. Gerontol. A Biol. Sci. Med. Sci., 69, 725, 10.1093/gerona/glt154 · DOI · Paper page
  84. Beggs, 2014, Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone, Am. J. Physiol. Endocrinol. Metab., 307, E456, 10.1152/ajpendo.00184.2014 · DOI
  85. Dhindsa, 2016, Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes, Clin. Endocrinol. (Oxf.), 85, 772, 10.1111/cen.13130 · DOI
  86. Gagliano-Juca, T., Pencina, K.M., Ganz, T., Travison, T.G., Kantoff, P.W., Nguyen, P.L., Taplin, M.E., Kibel, A.S., Li, Z., and Huang, G. (2018). Mechanisms Responsible for Reduced Erythropoiesis during Androgen Deprivation Therapy in Men with Prostate Cancer. Am. J. Physiol. Endocrinol. Metab. · DOI
  87. Lehtihet, M., Bonde, Y., Beckman, L., Berinder, K., Hoybye, C., Rudling, M., Sloan, J.H., Konrad, R.J., and Angelin, B. (2016). Circulating Hepcidin-25 Is Reduced by Endogenous Estrogen in Humans. PLoS ONE, 11. · DOI · Paper page
  88. Bajbouj, 2018, Elevated Levels of Estrogen Suppress Hepcidin Synthesis and Enhance Serum Iron Availability in Premenopausal Women, Exp. Clin. Endocrinol. Diabetes, 126, 453, 10.1055/s-0043-124077 · DOI
  89. Smith, 2015, Vitamin D and anemia: Insights into an emerging association, Curr. Opin. Endocrinol. Diabetes Obes., 22, 432, 10.1097/MED.0000000000000199 · DOI · Paper page
  90. Smith, 2017, High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults, Clin. Nutr., 36, 980, 10.1016/j.clnu.2016.06.015 · DOI · Paper page
  91. Smith, 2018, High-Dose Vitamin D3 Administration Is Associated with Increases in Hemoglobin Concentrations in Mechanically Ventilated Critically Ill Adults: A Pilot Double-Blind, Randomized, Placebo-Controlled Trial, JPEN J. Parenter. Enter. Nutr., 42, 87, 10.1177/0148607116678197 · DOI
  92. Atkinson, 2017, Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial, Pediatr. Nephrol., 32, 859, 10.1007/s00467-016-3563-6 · DOI
  93. Panwar, B., McCann, D., Olbina, G., Westerman, M., and Gutierrez, O.M. (2018). Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: A randomized controlled trial. BMC Nephrol., 19. · DOI
  94. Cooke, 2013, A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates, Blood, 122, 3054, 10.1182/blood-2013-06-505792 · DOI · Paper page
  95. Krzyzanski, 2016, Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys, AAPS J., 18, 713, 10.1208/s12248-016-9886-1 · DOI
  96. Abonour, 2017, A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia, J. Hematol. Oncol., 10, 73, 10.1186/s13045-017-0427-x · DOI · Paper page
  97. Rothe, 2018, Anticalin((R)) Proteins as Therapeutic Agents in Human Diseases, BioDrugs, 32, 233, 10.1007/s40259-018-0278-1 · DOI
  98. Veronese, 2008, The impact of PEGylation on biological therapies, BioDrugs, 22, 315, 10.2165/00063030-200822050-00004 · DOI · Paper page
  99. Vater, 2015, Turning mirror-image oligonucleotides into drugs: The evolution of Spiegelmer((R)) therapeutics, Drug Discov. Today, 20, 147, 10.1016/j.drudis.2014.09.004 · DOI · Paper page
  100. Boyce, 2016, Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects, Br. J. Pharmacol., 173, 1580, 10.1111/bph.13433 · DOI · Paper page
  101. Macdougall, I.C., Rumjon, A., Cinco, J., Goldstein, L., Summo, L., Vauleon, S., and Riecke, K. (2015). Pharmacokinetics and pharmacodynamics of lexaptepid, a novel anti-hepcidin molecule, in ESA-resistant haemodialysis patients. Nephrol. Dial. Transplant., 20. · doi:10.1093/ndt/gfv182.08
  102. Georgiev, P., Lazaroiu, M., Ocroteala, L., Grudeva-Popova, J., Gheorghita, E., Vasilica, M., Popescu, S.M., Cucuianu, A., Summo, L., and Schwoebel, F. (2014). The anti-hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study. Cancer Res., 74. · DOI
  103. Barrington, 2016, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure (Abstract), Blood, 128, 1280, 10.1182/blood.V128.22.1280.1280 · DOI

Cited by

Metadata

Authors
Katsarou, A., & Pantopoulos, K.
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2018-11-21
Volume
11
Issue
4
Pages
127
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4229492953
Cited by
112
References
79
FWCI
6.23
Type
journal article
Language
en
Open access
gold
Funders
Canadian Institutes of Health Research (PJT-159730)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.